<DOC>
	<DOC>NCT00436540</DOC>
	<brief_summary>The primary objective of this study is to evaluate the efficacy and safety of clobetasol propionate 0.05% (Clobex®) spray compared to clobetasol propionate 0.05% (Olux®) foam.</brief_summary>
	<brief_title>A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam</brief_title>
	<detailed_description>Same as above.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<criteria>Subjects must have a clinical diagnosis of moderate to severe plaque psoriasis, defined as 3%20% of the body surface area involved Subjects who have surface area involvement too large that would require more than 50 grams per week of Clobex® spray or more than 50 grams per week of Olux® foam Subjects whose psoriasis involves the scalp, face or groin Subjects with nonplaque psoriasis or other related diseases not classified as plaque psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>